Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 53 peer-reviewed journal articles Updated
Neurology

Your First Steps with ARSACS: Orientation and Validation

At a Glance

ARSACS is a rare, slowly progressive genetic disorder affecting balance, muscle stiffness, and nerve function. Despite causing mobility challenges over decades, most people with ARSACS have a near-normal life expectancy and can use physical therapy to maintain long-term independence.

Receiving a diagnosis of ARSACS can feel like the world has suddenly shifted beneath your feet. It is normal to feel overwhelmed, confused, or even isolated by the rarity of this condition. While the name is complex and the diagnosis is significant, you are now entering a phase of clarity. Understanding the facts of this condition is the first step in moving from uncertainty toward a plan for the future.

What is ARSACS?

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a rare, inherited neurodegenerative (a condition where nerve cells in the brain and body gradually lose function) disorder [1][2]. It is caused by mutations in the SACS gene, which provides instructions for making a protein called sacsin [3][4]. When this protein is missing or doesn’t work correctly, it affects how nerve cells communicate and survive [5].

The condition is usually identified by a “classic triad” of symptoms. For more details on how these symptoms develop, see The Symptoms and Biology of ARSACS.

  1. Cerebellar Ataxia: Difficulty with balance, coordination, and steady movement [1][6].
  2. Spasticity: Muscle stiffness or tightness, particularly in the legs [2][7].
  3. Peripheral Neuropathy: Damage to the nerves outside the brain and spinal cord, which can cause weakness or changes in sensation in the hands and feet [1][5].

Why the Name? (The Quebec Connection)

The name “Charlevoix-Saguenay” refers to two regions in Quebec, Canada, where the condition was first described in the late 1970s. In these regions, a founder effect occurred—meaning a small group of ancestors carried a specific genetic mutation that was passed down through generations within that specific population [8][5].

However, if you do not have French-Canadian heritage, you may wonder why you received this diagnosis. It is now known that ARSACS is a worldwide condition [8][2]. While the Quebec cases often share the same specific genetic mutations, cases found globally involve hundreds of different variations in the SACS gene [5][9]. No matter your background, the underlying cause—the lack of functional sacsin protein—is the same [3].

Stabilizing Facts for the Journey Ahead

While the word “progressive” can be frightening, it is important to understand the typical pace and nature of ARSACS:

01

Progression and What to Expect with ARSACS

Learn what to expect with ARSACS progression over time. Understand the mobility timeline, life expectancy, and how doctors track changes in coordination.

02

Diagnosing ARSACS: Understanding Genetics, MRI, and Eye Exams

Learn how ARSACS is diagnosed using brain MRIs, OCT eye exams, and genetic tests. Understand key report terms like SACS mutations and RNFL thickening.

Understanding the Timeline

Symptoms often appear in early childhood (usually between ages 2 and 5) as “clumsiness” or frequent falls [1][2]. While independence in walking is eventually affected—often requiring assistive devices or a wheelchair by the late 20s to 40s—every individual’s path is unique [2][12][7].

Important Note: This timeline reflects the classic early-onset form. If you were diagnosed later in adulthood, your symptom progression and mobility timeline will likely look very different [22][23]. Knowing what to expect allows you to build a supportive environment that prioritizes quality of life and long-term independence.

Common questions in this guide

What is ARSACS and what causes it?
ARSACS is a rare, inherited disorder that slowly affects the nervous system. It is caused by a mutation in the SACS gene, which prevents the body from making a functional protein called sacsin that nerve cells need to survive and communicate.
What are the main symptoms of ARSACS?
The condition is typically identified by a classic triad of symptoms. These include cerebellar ataxia (difficulty with balance and coordination), spasticity (muscle stiffness, primarily in the legs), and peripheral neuropathy (weakness or sensation changes in the hands and feet).
I don't have French-Canadian heritage. Can I still have ARSACS?
Yes. Although the condition was first discovered in a specific region of Quebec due to shared ancestry, ARSACS is a worldwide condition. People of any background can have different variations of the SACS gene mutation that cause the disorder.
Does ARSACS affect life expectancy?
Most individuals diagnosed with ARSACS have a normal or near-normal life expectancy. While the condition causes progressive mobility challenges over time, it is generally not considered a disease that significantly shortens your lifespan.
How do doctors confirm an ARSACS diagnosis?
Along with genetic testing, doctors often use a quick, non-invasive eye scan called Optical Coherence Tomography (OCT). This scan looks for a specific thickening of the retinal nerve fiber layer, which acts as a clear diagnostic fingerprint for the condition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the specific result of my (or my child's) SACS gene test, and how does it compare to the classic Quebec mutations?
  2. 2.Can we perform an OCT scan to look for retinal nerve fiber layer (RNFL) thickening to confirm the diagnosis and establish a baseline?
  3. 3.What do the MRI findings show regarding cerebellar atrophy or 'pontine stripes', and how does this affect the prognosis?
  4. 4.How would you describe the current rate of progression, and what clinical milestones (like loss of independent walking) should we realistically prepare for?
  5. 5.Are you familiar with the Cerebellar Cognitive Affective Syndrome (CCAS), and can we screen for any executive or emotional changes early on?
  6. 6.Which multidisciplinary specialists (physical therapy, neurology, ophthalmology) should be on our core care team?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Spastic ataxias.

    Bereznyakova O, Dupré N

    Handbook of clinical neurology 2018; (155()):191-203 doi:10.1016/B978-0-444-64189-2.00012-3.

    PMID: 29891058
  2. 2

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) in a Thai Patient: The Classic Clinical Manifestations, Funduscopic Feature, and Brain Imaging Findings with a Novel Mutation in the SACS Gene.

    Srikajon J, Pitakpatapee Y, Limwongse C, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2020; (10()):1 doi:10.5334/tohm.68.

    PMID: 32775015
  3. 3

    Reduction of sacsin levels in peripheral blood mononuclear cells as a diagnostic tool for spastic ataxia of Charlevoix-Saguenay.

    De Ritis D, Ferrè L, De Winter J, et al.

    Brain communications 2024; (6(4)):fcae243 doi:10.1093/braincomms/fcae243.

    PMID: 39091421
  4. 4

    Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.

    Longo F, De Ritis D, Miluzio A, et al.

    Neurology 2021; (97(23)):e2315-e2327 doi:10.1212/WNL.0000000000012962.

    PMID: 34649874
  5. 5

    Journey Through Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: Insights From a Case Series of Seven Patients-A Single-Center Study and Review of an Indian Cohort.

    Raval MA, Holla VV, Kamble N, et al.

    Journal of movement disorders 2024; (17(4)):430-435 doi:10.14802/jmd.24154.

    PMID: 39198013
  6. 6

    Teaching NeuroImages: Autosomal recessive spastic ataxia of Charlevoix-Saguenay: Typical MRI findings.

    Biswas A, Varman M, Yoganathan S, et al.

    Neurology 2018; (90(14)):e1271-e1272 doi:10.1212/WNL.0000000000005252.

    PMID: 29610238
  7. 7

    From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Gagnon C, Brais B, Lessard I, et al.

    Orphanet journal of rare diseases 2018; (13(1)):165 doi:10.1186/s13023-018-0898-z.

    PMID: 30231904
  8. 8

    A Probable Korean Case of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Kwon KY, Huh K, Eun BL, et al.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2015; (42(4)):271-3 doi:10.1017/cjn.2015.38.

    PMID: 26153042
  9. 9

    Genetic analysis of three patients from two unrelated Chinese families with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Liu H, Li R, Chen C, et al.

    BMC medical genomics 2025; (18(1)):83 doi:10.1186/s12920-025-02151-2.

    PMID: 40319245
  10. 10

    Absent Foveal Avascular Zone in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Douglas VP, Douglas KAA, Miller JB, Gaier ED

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2021; (41(2)):e166-e168 doi:10.1097/WNO.0000000000001050.

    PMID: 32991389
  11. 11

    An exploratory natural history of ataxia of Charlevoix-Saguenay: A 2-year follow-up.

    Gagnon C, Lessard I, Lavoie C, et al.

    Neurology 2018; (91(14)):e1307-e1311 doi:10.1212/WNL.0000000000006290.

    PMID: 30158165
  12. 12

    Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration.

    Bagaria J, Bagyinszky E, An SSA

    International journal of molecular sciences 2022; (23(1)) doi:10.3390/ijms23010552.

    PMID: 35008978
  13. 13

    ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.

    Salem IH, Blais M, Zuluaga-Sánchez VM, et al.

    Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.

    PMID: 39753868
  14. 14

    Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

    Vogel AP, Rommel N, Oettinger A, et al.

    Journal of neurology 2018; (265(9)):2060-2070 doi:10.1007/s00415-018-8950-4.

    PMID: 29968200
  15. 15

    Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Parkinson MH, Bartmann AP, Clayton LMS, et al.

    Brain : a journal of neurology 2018; (141(4)):989-999 doi:10.1093/brain/awy028.

    PMID: 29538656
  16. 16

    Retinal Architecture in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Insights into Disease Pathogenesis and Biomarkers.

    Rezende Filho FM, Bremner F, Pedroso JL, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(9)):2027-2035 doi:10.1002/mds.28612.

    PMID: 33893680
  17. 17

    A rehabilitation program to increase balance and mobility in ataxia of Charlevoix-Saguenay: An exploratory study.

    Lessard I, Masterman V, Côté I, et al.

    PloS one 2022; (17(12)):e0279406 doi:10.1371/journal.pone.0279406.

    PMID: 36576926
  18. 18

    Efficacy of Manual Wheelchair Skills Training for Improving Skills and Confidence in People With Hereditary Degenerative Disorders: Protocol for a Sequential Multimethods Study.

    Niyomwungere E, Routhier F, Gagnon C, et al.

    JMIR research protocols 2025; (14()):e66974 doi:10.2196/66974.

    PMID: 40742628
  19. 19

    Insights into SACS pathological attributes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)☆.

    Aly KA, Moutaoufik MT, Zilocchi M, et al.

    Current opinion in chemical biology 2022; (71()):102211 doi:10.1016/j.cbpa.2022.102211.

    PMID: 36126381
  20. 20

    Short Review: Investigating ARSACS: models for understanding cerebellar degeneration.

    Artero Castro A, Machuca C, Rodriguez Jimenez FJ, et al.

    Neuropathology and applied neurobiology 2019; (45(6)):531-537 doi:10.1111/nan.12540.

    PMID: 30636067
  21. 21

    In Vitro Characterization of Motor Neurons and Purkinje Cells Differentiated from Induced Pluripotent Stem Cells Generated from Patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Louit A, Beaudet MJ, Blais M, et al.

    Stem cells international 2023; (2023()):1496597 doi:10.1155/2023/1496597.

    PMID: 37096129
  22. 22

    SACS variants are a relevant cause of autosomal recessive hereditary motor and sensory neuropathy.

    Vill K, Müller-Felber W, Gläser D, et al.

    Human genetics 2018; (137(11-12)):911-919 doi:10.1007/s00439-018-1952-6.

    PMID: 30460542
  23. 23

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay without Spasticity.

    Aida I, Ozawa T, Fujinaka H, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(24)):3963-3967 doi:10.2169/internalmedicine.7401-21.

    PMID: 34121011

This page provides general orientation and educational information about an ARSACS diagnosis. It is not intended to replace professional medical advice from your neurologist or genetics team.

Get notified when new evidence is published on Autosomal recessive spastic ataxia of Charlevoix-Saguenay.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.